Lista de obras -

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing

scientific article published on 13 February 2019

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis

artículo científico publicado en 2020

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

scientific article published on 22 November 2019

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma

scientific article published on 28 August 2020

Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia

artículo científico publicado en 2017

Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment

scientific article published on 06 October 2020

Comparative analysis of staging systems in AL amyloidosis

scientific article published on 23 January 2019

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis

Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

artículo científico publicado en 2020

Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

artículo científico publicado en 2019

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

artículo científico publicado en 2018

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria

scientific article published on 01 January 2019

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma

artículo científico publicado en 2017

Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells

artículo científico publicado en 2020

Impact of acquired del(17p) in multiple myeloma

artículo científico publicado en 2019

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).

artículo científico publicado en 2017

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

artículo científico publicado en 2017

Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity

scientific article published on 30 December 2019

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

artículo científico publicado en 2017

Natural history of multiple myeloma with de novo del(17p)

scholarly article by Arjun Lakshman et al published 7 March 2019 in Blood Cancer Journal

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

scientific article published on 26 September 2018

Outcomes of primary refractory multiple myeloma and the impact of novel therapies

artículo científico publicado en 2015

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2019

Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis

artículo científico publicado en 2020

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome

scholarly article by Ashley R Paquin et al published 11 December 2018 in Blood Cancer Journal

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

scientific article published on 30 July 2018

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

article published in 2018

Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis

artículo científico publicado en 2017

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance

scientific article published on 30 January 2018

Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio

artículo científico publicado en 2020

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse

artículo científico publicado en 2018

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

artículo científico publicado en 2018

Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein

scientific article published on 15 August 2018

Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.

artículo científico publicado en 2015

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern

scientific article published on 12 July 2019

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

scientific article published on 06 May 2020

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

artículo científico

Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis

artículo científico publicado en 2017

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2018

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

artículo científico publicado en 2020

Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia

artículo científico publicado en 2020

Lista de obras de

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma

Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia

Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment

Comparative analysis of staging systems in AL amyloidosis

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis

Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma

Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells

Impact of acquired del(17p) in multiple myeloma

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

Natural history of multiple myeloma with de novo del(17p)

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

Outcomes of primary refractory multiple myeloma and the impact of novel therapies

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance

Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein

Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement

Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia